Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Leuk Lymphoma. 2018 Oct 2;60(4):1023–1029. doi: 10.1080/10428194.2018.1516036

Table 2.

Breakdown of reasons for off study treatment for newly diagnosed and relapsed / refractory patients. Percentages do not sum to 100% due to rounding.

Reason Off Study Newly diagnosed
(n=76)
Relapsed /
Refractory
(n=113)
Medical reason 28 (36%) 20 (18%)
High TRM score 9 (12%) 15 (13%)
Abnormal labs or cardiac function 8 (11%) 5 (4%)
Urgency to starting treatment 11 (14%) 0 (0%)
Logistical reason 42 (55%) 57 (50%)
Patient or physician preference 6 (8%) 24 (24)
Protocol not open 31 (41%) 28 (25%)
Financial constraints 5 (7%) 2 (2%)
Blast count too low 0 (0%) 3 (3%)
Unclear reason 6 (8%) 36 (32%)